Form 10-Q Ovid Therapeutics Inc. For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BTIG Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)
August 14, 2024 6:13 AM EDTBTIG analyst Thomas Shrader reiterated a Buy rating and $5.00 price target on Ovid Therapeutics Inc (NASDAQ: OVID).
The analyst comments "The P2 trial for OV888 in CCM is expected to start in 2H24 and could rapidly establish POC. The lesions (complex blood vessel tangles) are clearly visible in patients and treatment with OV888 has the chance to resolve them (not certain but seen in animal models). Similarly, OV329 is a safer Vigabatrin by design, so confirming safety in humans is highly de-risking, we believe. We hosted OVID management at the recent BTIG... More
